Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term follow-up of Infacort in pediatric adrenal insufficiency
2015-000458-40Phase 3Completed
- Sponsor
- Diurnal Group plc
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydrocortisone in congenital adrenal hyperplasia (CAH) and hypoadrenocorticism, sponsored by Diurnal Group plc. Primary endpoint: Safety (SAEs and AEs). Started Aug 2015; status: completed.
02
Drugs
hydrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)hypoadrenocorticism
Beyond the preview
Go deeper on 2015-000458-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000458-40.